Jubilant Life Sciences is currently trading at Rs. 792.00, up by 6.65 points or 0.85% from its previous closing of Rs. 785.35 on the BSE.
The scrip opened at Rs. 792.10 and has touched a high and low of Rs. 804.60 and Rs. 782.00 respectively. So far 105111 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 829.95 on 15-Mar-2017 and a 52 week low of Rs. 294.20 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 829.95 and Rs. 780.00 respectively. The current market cap of the company is Rs. 12599.14 crore.
The promoters holding in the company stood at 54.02 %, while Institutions and Non-Institutions held 26.50 % and 19.47 % respectively.
Jubilant Life Sciences’ material wholly owned subsidiary in Singapore - Jubilant Pharma (JPL) has received an approval to negotiate a potential acquisition of a speciality pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The board of directors of JPL at its meeting has approved for the same.
The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL’s existing business, if it materializes.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.